Pancreatic ductal adenocarcinoma: Clinical trials to watch

Vincent P. Groot; I. Quintus Molenaar; Geert A. Cirkel; Christopher L. Wolfgang; Hjalmar C. Van Santvoort

doi:10.1016/j.medj.2026.101268

Pancreatic ductal adenocarcinoma: Clinical trials to watch

Vincent P. Groot
, I. Quintus Molenaar
, Geert A. Cirkel
, Christopher L. Wolfgang
, Hjalmar C. Van Santvoort^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.

Original language	English
Article number	101268
Journal	Med
Volume	7
Issue number	9
DOIs	https://doi.org/10.1016/j.medj.2026.101268
Publication status	Published - 11 Sept 2026

Access to Document

10.1016/j.medj.2026.101268

Cite this

@article{55ca8a6abfc54347b9a5ff1580418485,

title = "Pancreatic ductal adenocarcinoma: Clinical trials to watch",

abstract = "The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.",

author = "Groot, \{Vincent P.\} and Molenaar, \{I. Quintus\} and Cirkel, \{Geert A.\} and Wolfgang, \{Christopher L.\} and \{Van Santvoort\}, \{Hjalmar C.\}",

note = "Publisher Copyright: {\textcopyright} 2026 Elsevier Inc.",

year = "2026",

month = sep,

day = "11",

doi = "10.1016/j.medj.2026.101268",

language = "English",

volume = "7",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - Pancreatic ductal adenocarcinoma

T2 - Clinical trials to watch

AU - Groot, Vincent P.

AU - Molenaar, I. Quintus

AU - Cirkel, Geert A.

AU - Wolfgang, Christopher L.

AU - Van Santvoort, Hjalmar C.

PY - 2026/9/11

Y1 - 2026/9/11

N2 - The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.

AB - The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.

UR - https://www.scopus.com/pages/publications/105050202965

U2 - 10.1016/j.medj.2026.101268

DO - 10.1016/j.medj.2026.101268

M3 - Comment/Letter to the editor

C2 - 42727566

AN - SCOPUS:105050202965

SN - 2666-6359

VL - 7

JO - Med

JF - Med

IS - 9

M1 - 101268

ER -

Pancreatic ductal adenocarcinoma: Clinical trials to watch

Abstract

Access to Document

Other files and links

Embargoed Document

Fingerprint

Cite this